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Background: Caspase-3 (CASP-3) is a primary effector CASP that 
executes programmed cell death, and it plays an important role in the 
development and progression of cancer. Polymorphisms in the CASP-
3 gene may inﬂuence CASP-3 production and/or activity, thereby 
modulating the susceptibility to lung cancer. To test this hypothesis, we 
investigated the association between CASP-3 polymorphisms and the 
risk of lung cancer in a Korean population. 
Methods: We ﬁrst screened single nucleotide polymorphisms (SNPs) 
in the CASP-3 gene by direct sequencing of genomic DNA samples 
taken from 27 healthy Korean individuals. We selected identiﬁed SNPs 
based on their frequency, linkage disequilibrium (LD) status and haplo-
type tagging status, and then genotyped the selected SNPs in 582 lung 
cancer patients and 582 healthy controls who were frequency matched 
for age and gender. 
Results: We identiﬁed eight SNPs: six known SNPs (-928A>G, 
246C>T, 829C>A, 1143G>C, 17532A>C and 20541C>T); and two 
novel SNPs (77G>A and 163G>T). Individuals with at least one variant 
allele of the -928A>G, 77G>A and 17532A>C polymorphisms were at 
a signiﬁcantly decreased risk for lung cancer in comparison to the carri-
ers with each homozygous wild-type allele [adjusted odds ratio (OR) = 
0.79, 95% conﬁdence interval (CI) = 0.62-1.00, P = 0.05; adjusted OR 
= 0.78, 95% CI = 0.61-0.99, P = 0.04; and adjusted OR = 0.74, 95% 
CI = 0.58-0.95, P = 0.02, respectively). Consistent with the results of 
genotyping analysis, the GAGC haplotype carrying the variant allele at 
all of the -928A>G, 77G>A, and 17532A>C loci was associated with a 
signiﬁcantly decreased risk of lung cancer compared to the AGGA hap-
lotype carrying no variant alleles at the three loci (adjusted OR = 0.66, 
95% CI = 0.51-0.86, P = 0.002 and Bonferroni corrected P = 0.008). 
Conclusions: These results suggest that the CASP-3 polymorphisms 
and their haplotypes contribute to the genetic susceptibility to lung 
cancer.
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Background: Improved early detection remains the most promising 
method of improving patient survival from lung cancer, and is a realis-
tic goal in the short term. This study reports the ﬁndings of a large scale 
trial evaluating a novel, fully automated method of DNA cytometry on 
sputum to detect lung cancer.
Methods: Over a period of 18 months, 1235 patients clinically suspi-
cious of having lung cancer were recruited into a multinational valida-
tion trial of the LungSign™ sputum test. Induced sputum was collected 
at the time of initial presentation, ﬁxed and treated with dithiothreitol 
(DTT). Papanicolaou stained smears were prepared and analysed by 
conventional cytology. Monolayer cytospin slides were prepared and 
stained using the Feulgen-thionin method. Cytospin slides were scored 
using LungSign, a test that uses a fully automated computerised DNA 
cytometry system to analyze thousands of epithelial cell nuclei to gen-
erate a measure associated with malignancy.
Results: Of the 1123 patients analysed, 370 proved to have lung cancer 
(prevalence 33%). The LungSign test provided an ROC “area under 
the curve” value of 0.692, and for a speciﬁcity of 91% it detected 40% 
of all lung cancers (Figure 1). Results were similar for all lung cancer 
histological types, as well as early (up to 1b) and later (stage 2a and 
above) stages. Conventional cytology detected 16% of cancers with a 
speciﬁcity of 99%. Approximately 12% of cytospins contained insuf-
ﬁcient epithelial cells for cytometric analysis. The inadequacy rate for 
conventional cytology was 43%.
Conclusions: In a high risk population, the LungSign test provides an 
effective means of detecting those patients most likely to have lung 
cancer. It is a continuous measure, permitting different cut points to be 
set. This ﬂexibility allows the test to be used in multiple contexts such 
as screening patients for lung cancer or evaluating suspicious lesions 
detected on CT, thereby directing efﬁcient use of other, more expensive 
and invasive diagnostic modalities.
Figure 1; ROC curve for the LungSign score, with conventional cytology 
(circle). Sensitivity and specificity standard error bars representing one stan-
dard deviation are shown.
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Background: Pre-clinical studies have shown that the majority of 
NSCLC have decreased expression of prostacyclin synthase (PGIS) and 
genetically modiﬁed mice with selective pulmonary PGIS overexpres-
sion are chemoprevented from developing lung cancer in a variety of 
models, including cigarette smoke exposure. Based on these promising 
results, a multi-center, double-blind, placebo controlled, phase II trial 
of iloprost (an oral prostacyclin analogue) in subjects at increased risk 
for lung cancer was initiated and continues to enroll.
Methods: Subjects are selected for the trial if they meet the follow-
ing criteria: current or former smoker (> 20 pack years); at least mild 
cytologic atypia on sputum cytology; no previous history of cancer. 
Fluorescent bronchoscopy is then performed with 6 standard sites biop-
sied, along with all other abnormally appearing areas. Subjects are then 
randomized to iloprost (in escalating doses) or placebo for 6 months 
and then undergo a repeat ﬂuorescent bronchoscopy with repeat biopsy 
of all the central airway areas sampled on the ﬁrst bronchoscopy. The 
primary endpoints for the study are bronchial histology and Ki-67 
